![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 39, 36391-36396, September 28, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
,
, and
¶
From the
Division of Clinical Biochemistry,
Department of Internal Medicine, University Medical Center, CH-1211
Geneva 4, Switzerland and § Department of Biochemistry,
School of Pharmacy, University of Barcelona, E-08028 Barcelona,
Spain
Received for publication, May 31, 2001, and in revised form, July 25, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Mitochondrial metabolism plays a pivotal role in
the pancreatic beta cell by generating signals that couple
glucose sensing to insulin secretion. We have demonstrated previously
that mitochondrially derived glutamate participates directly in the
stimulation of insulin exocytosis. The aim of the present study was to
impose altered cellular glutamate levels by overexpression of glutamate decarboxylase (GAD) to repress elevation of cytosolic glutamate. INS-1E
cells infected with a recombinant adenovirus vector encoding GAD65
showed efficient overexpression of the GAD protein with a parallel
increase in enzyme activity. In control cells glutamate levels were
slightly increased by 7.5 mM glucose (1.4-fold)
compared with the effect at 15 mM (2.3-fold)
versus basal 2.5 mM glucose. Upon GAD
overexpression, glutamate concentrations were no longer elevated by 15 mM glucose as compared with controls ( Mitochondrial metabolism plays a pivotal role in the pancreatic
beta cell by generating signals that couple glucose sensing to insulin
secretion (1-3). Initially, mitochondrial metabolism generates ATP,
which promotes the closure of ATP-sensitive K+ channels
and, as a consequence, the depolarization of the plasma membrane (4).
This leads to Ca2+ influx through voltage-gated
Ca2+ channels and a rise in cytosolic Ca2+
([Ca2+]c)1
triggering insulin exocytosis (4-6). However, the Ca2+
signal alone is not sufficient to reproduce the complete and sustained
secretion elicited by glucose (7-9). Therefore, glucose metabolism
must generate other factors participating in the stimulation of insulin
secretion. Such metabolites may be generated in different compartments,
the mitochondrion being the most likely source (10-12).
In permeabilized INS-1 cells, mitochondrial activation is associated
with a marked stimulation of insulin release, which depends both on
activation of the mitochondrial respiratory chain and on provision of
carbons for the tricarboxylic acid cycle (13, 14). This secretory
response requires a factor generated by mitochondrial metabolism
distinct from ATP (13, 15) proposed to be glutamate (14). This was
deduced from the finding that in permeabilized cells under conditions
of permissive, clamped [Ca2+]c, glutamate
directly stimulated insulin exocytosis (14). It was concluded that
glutamate acts downstream of mitochondrial function, participating in
the coupling of glucose metabolism to insulin secretion (11). Glutamate
can be formed in the mitochondria from the tricarboxylic acid cycle
intermediate Results obtained with a transgenic mouse model have indirectly
highlighted the putative role of intracellular glutamate in insulin
secretion. In these mice, overexpression of the
glutamate-decarboxylating enzyme GAD65 in the beta cells resulted in
glucose intolerance without any sign of insulitis or loss of beta
cells. Their islets showed impaired glucose-stimulated insulin
secretion, whereas the response to the Ca2+-raising agent
KCl was preserved (19). Although the authors have not measured the
glutamate levels in the pancreatic islets of these transgenic mice,
they discussed the possibility of reduced cellular glutamate levels as
one possible explanation for the diminished response to glucose. Hence,
the decrease in cellular glutamate levels can theoretically be achieved
by overexpression of glutamate decarboxylase. Upon appropriate
expression, this cytosolic enzyme decarboxylates glutamate produced by
the mitochondria after its release into the cytosol. Consequently,
cytosolic glutamate could be specifically reduced even during glucose
stimulation without affecting major metabolic pathways. The
Cell Culture--
Clonal INS-1E cells (22), derived and selected
from the parental rat insulinoma INS-1 cell line (23), were cultured in RPMI 1640 medium with 5% fetal calf serum. Adenovirus amplification was performed in HEK-293 cells cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum. Adherent cultured
INS-1E cells were infected with recombinant adenovirus for 90 min at 37 °C, washed once, and further cultured in complete RPMI 1640 medium for 18-20 h before experiments were performed. Pancreatic islets were isolated by collagenase digestion from male Wistar rats
weighing 200-250 g (24) and cultured free floating in RPMI 1640 medium
for 24 h before adenovirus transduction.
Adenovirus Construction--
The recombinant human 65-kDa
isoform of glutamic acid decarboxylase (GAD65) was used for the
adenovirus construct (25). Recombinant adenovirus encoding GAD65 under
the chicken actin promoter (26) was generated as previously described
(27). The plasmid hGAD65-pcDNA3 containing full-length human GAD65
cDNA was kindly provided by Drs. F. C. Schuit and F. Gorus
(Brussels, Belgium), originally obtained from Drs. A. Lernmark and A. Falorni when at the Karolinska Institute (Stockholm, Sweden) (28).
Following BamHI-XbaI digestion, the insert with
blunt ends was subcloned in a cosmid pAdCAG (27), previously opened by
SwaI. The presence and right orientation of the insert was
checked by restriction enzyme digestions using ClaI and
BglII. The cosmid containing hGAD65 (pAd-CAG-hGAD65) and the
adenovirus type 5 DNA terminal protein complex were co-transfected
using the calcium phosphate method (CellPhect, Amersham Pharmacia
Biotech) in HEK-293 cells, which were seeded in 96-well plates.
Ten days after transfection the cell lysate was used to infect 24-well
plates, and the adenoviral DNA was extracted from the cells and
analyzed by DNA digestion with ClaI and XhoI to
check for the presence of hGAD65. The cell lysate containing the virus
with full-length hGAD65 (AdCA-GAD65) was used to infect two 138-mm
dishes of HEK-293 cells. The virus was purified by CsCl
ultracentrifugation. AdCA-lacZ, which expresses bacterial
Immunoblotting and Immunofluorescence--
Cultured INS-1E cells
were infected with different clones of recombinant adenovirus (from
HEK-293 cell homogenates) for 90 min in a tissue culture incubator the
day prior to analysis. Immunoblotting was performed following
SDS-polyacrylamide gel electrophoresis using 10-µg proteins of INS-1E
cell extract per lane on an 11% gel. Proteins were transferred onto
nitrocellulose membrane and incubated overnight at 4 °C in the
presence of rabbit anti-GAD polyclonal antibody (1:2000) raised against
human GAD65 (Chemicon, Temecula, CA). The membrane was then incubated
for 1 h at room temperature with donkey anti-rabbit IgG antibody
(1:5000) conjugated to horseradish peroxidase (ECL, Amersham Pharmacia
Biotech), and the GAD protein was revealed by chemiluminescence
(Pierce). The adenovirus clone 11 was selected, purified, and used for
the following experiments.
For immunofluorescence, cells were grown on polyornithine-treated glass
coverslips for 3 days prior to infection with AdCA-LacZ or AdCA-GAD
(~100 PFU/cell) for 90 min. The next day, cells were fixed as
previously described (29) before incubation with anti-GAD (1:1000) and
then goat anti-rabbit IgG rhodamine (1:200) antibodies (Chemicon).
Cells were viewed using a Zeiss laserscan confocal 410 microscope.
GAD Activity and Glutamate Level Determination--
INS-1E cells
were cultured 2-3 days in 6-well plates, infected with AdCA-GAD65 or
AdCA-lacZ in 1 ml of RPMI 1640 medium for 90 min at ~40 PFU/ml, and
thereafter supplemented with fresh medium. After 18 h the cells
were washed with cold phosphate-buffered saline, collected with a
rubber policeman in 50 µl of a lysis buffer (0.5 M
HEPES-NaOH, pH 7.0, 10 mM NaF, 2 mM
aminoethylisothiouronium bromide hydrobromide, 2 mM
phenylmethylsulfonyl fluoride, 0.05% Triton X-100), and kept on ice
for 1 h in 1.5-ml tubes. Cells were then centrifuged at 13,000 rpm
for 30 min at 4 °C to eliminate cellular membranes. After
centrifugation, the supernatant was collected and diluted 1:10 in lysis
buffer without Triton before protein determination (Bradford's assay).
Aliquots (100 µl) of this protein sample were injected into cups
containing 100 µl of a glutamate mixture (0.5 M
HEPES-NaOH, pH 7.0, 0.2 mM pyridoxal phosphate, 2 mM glutamate, 0.1 µCi of
L-[1-14C]glutamate (ARC, St. Louis, MO)), and
placed in sealed vials. After a 1-h incubation at 37 °C the reaction
was stopped by adding 100 µl of 7% perchloric acid, and
CO2 was captured by the addition of 300 µl of
benzethonium hydroxide. Diluted lysis buffer was used as a blank. After
5 h the cups were removed and 10 ml of scintillation liquid was
added to the vials. After 24 h the radioactivity was measured in a
For cellular glutamate determination INS-1E cells were cultured 2-3
days in 10-cm Petri dishes, infected with AdCA-GAD65 or AdCA-lacZ for
90 min, and supplemented with fresh medium. After 18 h the cells
were preincubated for 2 h in glucose- and glutamine-free RPMI 1640 medium at 37 °C. Cells were then incubated for 30 min at 37 °C in
Krebs-Ringer bicarbonate HEPES buffer (KRBH) containing (in
mM): 135 NaCl, 3.6 KCl, 10 HEPES (pH 7.4), 5 NaHCO3, 0.5 NaH2PO4, 0.5 MgCl2, 1.5 CaCl2, and 2.5/7.5 or 15 glucose.
The stimulation period was stopped by putting the cells on ice. After
discarding the incubation buffer 1 ml of lysis buffer (20 mM Tris-HCl, pH 8.0, 2 mM CDTA, 0.2% Tween 20)
was added to the cells. Glutamate levels were measured in cell
homogenates by monitoring NADH fluorescence as previously described
(14).
Mitochondrial Membrane Potential and ATP Generation--
INS-1E
cells were cultured 2-3 days, infected with AdCA-GAD65 or AdCA-lacZ
for 90 min at ~40 PFU/ml, and used for experiments the next day.
Mitochondrial membrane potential ( Insulin Secretion Assay--
INS-1E cells cultured in 24-well
plates were infected over a 90-min period with either AdCA-GAD65 or
AdCA-LacZ adenovirus at ~40 PFU/cell and assayed the next day. Prior
to the experiments, cells were maintained for 2 h in glucose- and
glutamine-free culture medium. The cells were then washed and
preincubated further in glucose-free KRBH, supplemented with 0.1%
bovine serum albumin (Sigma) added as carrier, before the incubation
period (30 min at 37 °C) with different glucose concentrations or
KCl. For GABA experiments, cells were cultured and incubated in the
same way except for adenovirus infection.
Isolated rat islets were infected with either AdCA-GAD65 or AdCA-LacZ
adenovirus over a 90-min period the day after isolation and further
cultured for 24 h before the secretion assay. Islet perifusions
were carried out using 20 islets per chamber of 250 µl volume
thermostated at 37 °C (Brandel, Gaithersburg, MD). The flux was set
at 0.5 ml/min, and fractions were collected every minute following a
20-min washing period at basal glucose (2.8 mM). Insulin
secretion was determined by radioimmunoassay using rat insulin as
standard (14).
Statistical Analyses--
Where applicable, the results were
expressed as means ± S.E., and differences between groups were
analyzed by Student's t test.
Assessment of Adenovirus-mediated GAD65
Overexpression--
Several clones of adenoviruses were amplified in
HEK-293 cells before testing their ability to overexpress GAD65 in
target cells. Insulinoma INS-1E cells cultured in 6-well plates for 4 days were infected over a 90-min period with homogenates of HEK-293 cells used to amplify adenovirus. Immunoblotting performed the next day
using anti-human GAD65 antibody revealed a band at the expected size of
65 kDa. As shown on one representative immunoblot (Fig.
1A), clone 11 gave a clean
signal at 65 kDa detected as a likely doublet (32). The recombinant
adenovirus was further validated by DNA digestion and selected for
virus amplification, purification, and use throughout the study. This
virus preparation was then referred to as AdCA-GAD65. The control
adenovirus, which expresses bacterial
Cellular localization of GAD65 in control and INS-1E cells infected
with AdCA-GAD65 was investigated by immunofluorescence performed the
day after a 90-min infection using purified virus preparations. Reetz
et al. (33) have shown that in pancreatic beta cells GAD is
localized around synaptic-like microvesicles, probably without direct
connection. Immunofluorescence on control INS-1E cells using anti-GAD65
antibody revealed a punctuate pattern for these cells expressing only
basal levels of GAD65, suggesting co-localization with vesicles (Fig.
1B). In contrast, cells overexpressing GAD65 following
AdCA-GAD65 infection exhibited strong, diffuse fluorescence mainly in
the cytosolic compartment (Fig. 1C).
GAD Activity and Glutamate Levels in INS-1E Cells--
INS-1E
cells were infected with either AdCA-GAD65 or AdCA-LacZ adenovirus and
analyzed the next day. GAD activity in cell extracts was measured as
the GAD-mediated decarboxylation of
L-[1-14C]glutamate to
14CO2. It was dramatically increased by
overexpression of GAD65 (Fig.
2A). Infection of INS-1E cells
with the control AdCA-LacZ virus did not modify GAD activity, neither
at 40 PFU/cell nor at 400 PFU/cell, compared with non-infected cells
(0.09 ± 0.03 pmol of CO2/min/µg of protein). On the
other hand, infection with AdCA-GAD65 virus resulted in a marked and
dose-dependent increase in GAD activity: 26-fold at 40 PFU/cell and up to 102-fold at 400 PFU/cell compared with corresponding
AdCA-LacZ controls (p < 0.0001 for both). These are
in vitro, optimal enzyme activities from cell lysates,
probably higher than the effective cellular activity. For the following
experiments we selected an infection titer of 40 PFU/cell, which was
sufficient for high GAD activity without noticeable virus-mediated cell
toxicity.
Next, cellular glutamate contents were determined, because the aim of
overexpressing GAD was to affect the cytosolic glutamate levels,
especially during glucose stimulation. In control cells (AdCA-LacZ-infected) cellular glutamate content was elevated, as
expected, after a 30-min glucose stimulation (Fig. 2B).
Compared with 2.5 mM glucose (2.69 ± 0.25 nmol of
glutamate/mg of protein), incubation at 7.5 and 15 mM
glucose resulted in 1.4-fold (p < 0.05) and 2.3-fold
(p < 0.05) glutamate increases, respectively. In cells
overexpressing GAD following infection with AdCA-GAD65 virus, the basal
levels were reduced by 36% (p < 0.05). Glucose stimulation failed to increase efficiently cellular glutamate contents
at both 7.5 and 15 mM glucose. This resulted in a 40% reduction of glutamate levels at 15 mM glucose compared
with stimulated control cells (p < 0.02). Using a
higher titer of AdCA-GAD65 virus (120 PFU/cell), there was no further
decrease of glutamate levels (data not shown).
Mitochondrial Membrane Potential and ATP Generation--
In
control cells mitochondrial membrane potential was hyperpolarized by
raising glucose from 2.5 to 15 mM and by the addition of
the protonophore carbonyl cyanide
p-trifluoromethoxyphenylhydrazone (FCCP) resulted in a rapid
depolarization. Similar effects were observed in cells overexpressing
GAD (Fig. 3A). Activation of the electron transport chain, measured here as the potential of the
mitochondrial membrane, leads to the formation of ATP. In accordance
with mitochondrial membrane potential, ATP generation was not affected
by GAD overexpression. Indeed, cytosolic ATP levels monitored in cells
expressing luciferase were elevated to similar extents by raising
glucose from 2.5 to 15 mM (Fig. 3B). ATP
generation was also measured in cell lysates following a 10-min
incubation period at low and high glucose. ATP levels at 15 mM glucose compared with 2.5 mM were elevated
by 23.1% (367 ± 5 versus 298 ± 1 nmol/mg of
protein, respectively, p < 0.005) in AdCA-LacZ control
cells and by 27.9% (413 ± 22 versus 322 ± 14 nmol/mg of protein, respectively, p < 0.05) in
AdCA-GAD65 cells (means of three independent experiments). Therefore,
GAD overexpression did not alter the activity of the electron transport
chain.
Effects of GAD Overexpression on Insulin Secretion in INS-1E
Cells--
INS-1E cells cultured in 24-well plates were infected at
~40 PFU/cell and assayed the next day. Following a preincubation period and washes in glucose-free buffers, cells were challenged for 30 min with different glucose concentrations. Insulin secretion was also
stimulated at basal 2.5 mM glucose with 30 mM
KCl, as a Ca2+ raising agent, to assess for anaplerotic
effects. In control cells (AdCA-LacZ-infected), raising glucose from
basal 2.5 to 7.5 and 15 mM stimulated insulin secretion
2.5-fold (p < 0.05) and 5.2-fold (p < 0.01), respectively (Fig. 4A).
Insulin release at basal (2.5 mM) or intermediate (7.5 mM) glucose concentration was not affected in cells
overexpressing GAD (AdCA-GAD65). In contrast, insulin secretion
stimulated by 15 mM glucose (2.6-fold versus
basal glucose, p < 0.05) was inhibited by 37%
(p < 0.05) compared with the corresponding control at
high glucose. The effects of 30 mM KCl on insulin
exocytosis were similar in control cells and cells overexpressing GAD.
As shown in Fig. 4B, insulin secretion correlated positively
with cellular glutamate levels (R2 = 0.8474, p < 0.05), remarkably evident at high glucose
concentration.
It has been shown that glutamate decarboxylation by GAD forms GABA in
pancreatic islets (34), which may be released from synaptic-like
microvesicles (35, 36). The effect of extracellular GABA on the beta
cell is controversial; GABA has been postulated to inhibit insulin
secretion (37), although this effect could not be confirmed (20). Cells
overexpressing GAD following AdCA-GAD65 infection and stimulation with
high glucose could therefore theoretically release significant amounts
of GABA with a possible negative feedback on insulin secretion. In this
context, it was felt necessary to check for any potential effect of
GABA added in the medium during stimulation of insulin secretion.
Exposure of INS-1E cells to GABA up to 100 µM did not
alter glucose-induced insulin secretion (Fig.
5), rendering unlikely a GABA-mediated
inhibitory effect on exocytosis in cells overexpressing GAD.
Effect of GAD Overexpression on Insulin Secretion in Rat
Islets--
Cultured rat islets infected with the control AdCA-LacZ
virus responded to glucose stimulation by a sustained increased rate of
insulin secretion at 8.3 mM glucose, which rose further at 16.7 mM glucose (Fig.
6A). Overexpression of GAD65,
assessed by immunoblotting, had no significant effects at basal (2.8 mM) or intermediate (8.3 mM) glucose
concentrations. In contrast, at 16.7 mM glucose the
secretory response was reduced by 31% in islets infected with
AdCA-GAD65 compared with controls (area under the curve = 4.43 ± 0.63 versus 6.41 ± 1.23 (insulin release
as % content), respectively, p < 0.05). Stimulation
of insulin secretion by high potassium-induced membrane depolarization
resulted in a transient elevation of the secretory response in control
islets (Fig. 6B). Overexpression of GAD did not modify this
non-metabolic response. These results are in accordance with those
obtained in the clonal beta cell line INS-1E, i.e.
inhibition of insulin secretion stimulated by glucose but not by
potassium.
The role of GAD in the beta cell is under intense study because it
has been recognized as an autoantigen in insulin-dependent diabetes (38). GAD65 is the form predominantly expressed in rats and
humans, localized mainly in brain and pancreatic islets (21). The
purpose of the present study was to overexpress GAD65 in beta cells to
lower the levels of glutamate through decarboxylation during glucose
stimulation. This was achieved by the use of a recombinant adenovirus
vector encoding human GAD65 in beta cells. Hence, we could substantiate
the proposed role for glutamate as a metabolic coupling factor
participating in glucose-induced insulin secretion (14).
In pancreatic beta cells, GAD was shown to be associated with
synaptic-like microvesicles, although GAD was also found in the cytosol
(33, 39). Michalik and co-workers (34) demonstrated that in fractions
from homogenates of rat pancreatic islets, GAD activity was mainly
recovered in the cytosol (51%) with lesser enrichment in the
microsomes (17%). In our study, immunofluorescence of GAD65 revealed a
punctuate pattern in control cells, whereas INS-1E cells overexpressing
GAD65 exhibited strong cytosolic-like fluorescence. Therefore, it would
seem that overexpression of GAD65 does not lead to a noticeable
increase in vesicle attachment, essentially accumulating freely in the
cytosol. This observation is in agreement with the previous proposal
for an indirect or labile interaction of GAD with vesicles (33).
The control of insulin secretion by the pancreatic beta cell is
achieved through a complex metabolic cascade converting glucose and
other nutrients into signals leading to appropriate insulin release (3,
12). Mitochondrial metabolism is crucial in generating ATP leading to a
rise in [Ca2+]c, which is the main and necessary
signal triggering insulin exocytosis (4, 6). However, other factors
generated by glucose participate in the stimulation of insulin
secretion and have attracted much interest over the last years (9). In this context, the beta cells of a transgenic mouse model have recently
been reported to exhibit impaired insulin secretion in response to
glucose but not to KCl, a [Ca2+]c-raising agent
(19). These mice overexpressing GAD65 specifically in beta cells
exhibited impaired glucose tolerance and inhibition of insulin
secretion in response to glucose, without any insulitis or loss of beta
cells. Overexpression of the glutamate-decarboxylating enzyme in beta
cells could theoretically lead to decreased cellular glutamate levels.
The reduced insulin secretion observed in these mice is compatible with
the proposal that mitochondrially derived glutamate participates in
glucose-stimulated insulin secretion (11, 14).
Glutamate levels in control INS-1E cells were increased following
glucose stimulation. Overexpression of GAD65 resulted in high GAD
activity and reduced cellular glutamate levels, whereas the
mitochondrial activation was preserved. The present study demonstrates
the feasibility of specifically reducing cellular glutamate levels
mediated by controlled GAD overexpression. This leads to an elevated
glutamate decarboxylation rate, essentially in the cytosol (34). The
decrease in cellular glutamate levels correlated with impaired insulin
secretion stimulated by high glucose. It is noteworthy that the major
effects were observed above basal and intermediate glucose
concentrations, suggesting a threshold phenomenon for glutamate action.
This is compatible with a role of a potentiator for glutamate in
conditions of permissive [Ca2+]c. Indeed, the
effect of the [Ca2+]c-raising agent (30 mM KCl) was not affected by GAD overexpression, also
indicating that exocytosis per se was preserved. Very
similar results were obtained using isolated rat pancreatic islets
overexpressing GAD. This is in good agreement with pancreatic perfusions performed in mice overexpressing GAD65 in the beta cells,
although this study did not examine the glutamate pathway (19). Taken
together these data argue in favor of a role for glutamate as a factor
derived from glucose participating in the stimulation of insulin
secretion. One hypothetical mechanism is that glutamate would favor
granule priming for exocytosis, a mechanism which might not be
restricted to the beta cell. In this context it is of interest that
clonal pancreatic alpha cells, secreting glucagon, have recently been
shown to accumulate glutamate in their vesicles and to release it upon
stimulation (40).
The high GAD activity resulting from GAD65 overexpression may
substantially increase GABA generation and release. During high glucose
culture, GABA was shown to be released from pancreatic beta cells (35,
36). Once in the extracellular space, GABA could act on neighboring
islet alpha cells, inhibiting glucagon secretion through activation of
GABA-A receptors (41). Although these receptors have not been
identified on beta cells, it has been suggested that GABA inhibits
insulin secretion in dogs (37), an effect that could not be reproduced
in mice or rats (20). In this context, we checked for any potential
effect of GABA on glucose-stimulated insulin secretion in INS-1E cells
derived from a rat insulinoma. There was no effect of GABA added to the
medium up to 100 µM, a concentration far above the
estimate of GABA release by beta cells (35, 36).
In the present study the overexpression of GAD65 was used to test the
proposed role for glutamate as a coupling factor in glucose-stimulated
insulin secretion. The data support the model in which glutamate would
act as a potentiator of insulin release, sensitizing exocytosis to the
effect of calcium. Indeed, the effect of elevated glucose concentration
was inhibited by high GAD activity, whereas intermediate glucose or KCl
stimulation was not affected by GAD overexpression. GAD overexpression
could also clarify the role of GABA as a paracrine factor in the islet.
40%). Insulin secretion was stimulated in control cells by glucose at 7.5 mM (2.5-fold) and more efficiently at 15 mM
(5.2-fold). INS-1E cells overexpressing GAD exhibited impaired insulin
secretion on stimulation with 15 mM glucose (
37%). The
secretory response to 30 mM KCl, used to raise cytosolic
Ca2+ levels, was unaffected. Similar results were obtained
in perifused rat pancreatic islets following adenovirus transduction.
This GAD65-mediated glutamate decarboxylation correlating with impaired glucose-induced insulin secretion is compatible with a role for glutamate as a glucose-derived factor participating in insulin exocytosis.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-ketoglutarate by glutamate dehydrogenase (17). In the
beta cell, we have shown that glutamate is generated by the
mitochondria during glucose stimulation (14, 16), although such changes
have not been observed by others (18). The inherent problem in studies
on cellular glutamate contents is the absence of methods allowing determination of glutamate levels in the relevant cellular compartment, i.e. the cytosol. Hence, because the net cellular changes
are still controversial (11, 14, 18), further substantiation of the
role of glutamate requires modulation of its cytosolic levels, which is
the aim of the present study.
-aminobutyric acid (GABA) thus formed is not believed to affect
insulin secretion (20). In the present study the smaller isoform of
glutamate decarboxylase, GAD65, predominantly expressed in rat
pancreatic islets (21), has been overexpressed in rat insulinoma INS-1E cells and rat pancreatic islets. To control the expression of GAD65 a
recombinant adenovirus vector encoding GAD65 was prepared. Overexpression of GAD65 in beta cells resulted in reduced glutamate levels and impaired glucose-stimulated insulin secretion.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-galactosidase, was used as a control adenovirus.
counter (LS6500, Beckman Coulter, Fullerton, CA).

m) was measured as
described (13) using rhodamine-123. Cells were used as a suspension in
KRBH buffer, gently stirred in a fluorimeter cuvette at 37 °C, and
fluorescence, excited at 490 nm, was measured at 530 nm. Cytosolic ATP
levels were monitored in cells expressing the ATP-sensitive
bioluminescent probe luciferase following infection with the specific
viral construct (30, 31). ATP generation was also assessed in 6-well
plates following a 2-h preincubation period in glucose-free RPMI 1640. Cells were incubated for 10 min in KRBH with 2.5 mM or 15 mM glucose before the stimulation was stopped on ice by
washing with ice-cold KRBH and the addition of 0.4 N
HClO4. ATP levels were determined using a bioluminescence assay kit (HS II, Roche Diagnostic, Rotkreuz, Switzerland).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-galactosidase, was called
AdCA-LacZ.

View larger version (17K):
[in a new window]
Fig. 1.
Adenovirus-mediated GAD65
overexpression. A, immunoblotting using anti-GAD65
antibody in insulinoma INS-1E cells. These were cultured in 6-well
plates for 4 days, infected over a 90-min period with homogenates of
different clones of adenovirus-containing HEK-293 cells, and collected
the following day for immunoblotting. Clone 11 was selected for use
throughout the study and referred to AdCA-GAD65. B, cellular
localization of GAD65 in INS-1E cells investigated by
immunofluorescence using anti-GAD65 antibody performed the day after
infection with purified virus preparations. Control INS-1E cells were
infected with AdCA-LacZ virus. C, cells overexpressing GAD
were infected with the AdCA-GAD65 virus. Observations are
representative of three to five independent experiments.

View larger version (18K):
[in a new window]
Fig. 2.
GAD activity and glutamate levels in INS-1E
cells. INS-1E cells were infected over a 90-min period with either
AdCA-GAD65 or AdCA-LacZ adenovirus and analyzed the next day.
A, GAD activity in cell extracts was measured as the
GAD-mediated decarboxylation of
L-[1-14C]glutamate to
14CO2. Values are means ± S.D.
representing one of a total of four experiments. An infection titer of
40 PFU/cell was selected for the following experiments. B,
cellular glutamate levels were determined following a 30-min incubation
in the presence of basal (2.5 mM) or stimulatory (7.5 and
15 mM) glucose concentrations. Values are the means ± S.E. for three independent experiments, *, p < 0.05 versus 2.5 mM glucose; §, p < 0.05; §§, p < 0.02 versus AdCA-LacZ at
corresponding glucose concentrations.

View larger version (20K):
[in a new window]
Fig. 3.
Mitochondrial membrane potential and ATP
generation. INS-1E cells were cultured 2-3 days, infected with
AdCA-GAD65 or AdCA-lacZ for 90 min at ~40 PFU/ml, and used for
experiments the next day. A, mitochondrial membrane
potential was monitored as rhodamine-123 fluorescence. Each trace
started at 2.5 mM glucose, which was then raised to 15 mM before complete depolarization induced by 1 µM FCCP. B, cytosolic ATP levels were
monitored in cells expressing the ATP-sensitive bioluminescent probe
luciferase. Traces are representative of three independent experiments.
See "Results" for data and statistics on static incubations.

View larger version (18K):
[in a new window]
Fig. 4.
Effect of GAD overexpression on insulin
secretion in INS-1E cells. A, INS-1E cells cultured in
24-well plates were infected over a 90-min period with either
AdCA-GAD65 or AdCA-LacZ adenovirus and assayed the next day. Following
a preincubation period and rinsing in glucose-free buffer, cells were
challenged for 30 min with 2.5, 7.5, and 15 mM glucose or
30 mM KCl (at 2.5 mM glucose). Values are the
means ± S.E. for four independent experiments, *,
p < 0.05; and **, p < 0.01 versus 2.5 mM glucose; §, p < 0.05 versus AdCA-LacZ at 15 mM glucose.
B, correlation between cellular glutamate levels and insulin
secretion from data extracted from Figs. 2B and
4A, respectively. Triangles represent LacZ
controls and squares the GAD overexpressing cells, each
incubated at different glucose concentrations (2.5, 7.5, and 15 mM).

View larger version (17K):
[in a new window]
Fig. 5.
Effect of GABA on insulin secretion in INS-1E
cells. INS-1E cells cultured in 24-well plates were preincubated
and washed in glucose-free buffer before incubation for 30 min at 2.5 or 15 mM glucose in the presence of increasing
concentrations of GABA. Values are the means ± S.E. for four
independent experiments, *, p < 0.05 versus
2.5 mM glucose.

View larger version (21K):
[in a new window]
Fig. 6.
Effect of GAD overexpression on insulin
secretion in rat islets. Isolated rat islets were infected with
either AdCA-GAD65 or AdCA-LacZ adenovirus over a 90-min period the day
after isolation and further cultured for 24 h before secretion
assay. Islet perifusions were carried out using 20 islets per chamber
at 0.5 ml/min, and fractions were collected every minute. A,
after a period at 2.8 mM glucose, insulin secretion was
stimulated by raising glucose to 8.3 mM for 15 min directly
followed by 15 min at 16.7 mM glucose, then returning to
2.8 mM. B, islets were exposed to 30 mM KCl for 10 min at the constant basal glucose
concentration of 2.8 mM. Values are means ± S.E. for
three independent experiments, see "Results" for statistics.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank G. Chaffard and C. Bartley for excellent technical assistance as well as P. A. Antinozzi and F. C. Schuit for stimulating discussions.
| |
FOOTNOTES |
|---|
* This study was supported by a fellowship from the University of Barcelona (to B. R.), the Juvenile Diabetes Foundation International (to H. I.), Swiss National Science Foundation Grant 32-49755.96 (to C. B. W.), and the Paul Langerhans Research Fellowship from the European Association for the Study of Diabetes (to P. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Division de Biochimie Clinique, Center Médical Universitaire, 1 rue Michel-Servet, CH-1211 Geneva 4, Switzerland. Tel.: 41-22-702-55-54; Fax: 41-22-702-55-43; E-mail: pierre.maechler@medecine.unige.ch.
Published, JBC Papers in Press, July 25, 2001, DOI 10.1074/jbc.M104999200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
[Ca2+]c, cytosolic [Ca2+];
FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone;
GABA,
-aminobutyric acid;
GAD, glutamate decarboxylase;
KRBH, Krebs-Ringer
bicarbonate HEPES buffer;
PFU, plaque-forming unit.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Newgard, C. B., and McGarry, J. D. (1995) Annu. Rev. Biochem. 64, 689-719 |
| 2. | Prentki, M. (1996) Eur. J. Endocrinol. 134, 272-286 |
| 3. | Wollheim, C. B. (2000) Diabetologia 43, 265-277 |
| 4. | Rorsman, P. (1997) Diabetologia 40, 487-495 |
| 5. | Wollheim, C. B., Lang, J., and Regazzi, R. (1996) Diabetes Rev. 4, 276-297 |
| 6. | Lang, J. (1999) Eur. J. Biochem. 259, 3-17 |
| 7. | Gembal, M., Gilon, P., and Henquin, J. C. (1992) J. Clin. Invest. 89, 1288-1295 |
| 8. | Sato, Y., Aizawa, T., Komatsu, M., Okada, N., and Yamada, T. (1992) Diabetes 41, 438-443 |
| 9. | Henquin, J. C. (2000) Diabetes 49, 1751-1760 |
| 10. | Corkey, B. E., Deeney, J. T., Yaney, G. C., Tornheim, K., and Prentki, M. (2000) J. Nutr. 130 (suppl.), 299S-304S |
| 11. | Maechler, P., and Wollheim, C. B. (2000) J. Physiol. (Lond.) 529, 49-56 |
| 12. | Schuit, F. C., Huypens, P., Heimberg, H., and Pipeleers, D. G. (2001) Diabetes 50, 1-11 |
| 13. | Maechler, P., Kennedy, E. D., Pozzan, T., and Wollheim, C. B. (1997) EMBO J. 16, 3833-3841 |
| 14. | Maechler, P., and Wollheim, C. B. (1999) Nature 402, 685-689 |
| 15. | Maechler, P., Kennedy, E. D., Wang, H., and Wollheim, C. B. (1998) J. Biol. Chem. 273, 20770-20778 |
| 16. | Maechler, P., Antinozzi, P. A., and Wollheim, C. B. (2000) IUBMB Life 50, 27-31 |
| 17. | Hudson, R. C., and Daniel, R. M. (1993) Comp. Biochem. Physiol. B 106, 767-792 |
| 18. | MacDonald, M. J., and Fahien, L. A. (2000) J. Biol. Chem. 275, 34025-34027 |
| 19. | Shi, Y., Kanaani, J., Menard-Rose, V., Ma, Y. H., Chang, P.-Y., Hanahan, D., Tobin, A., Grodsky, G., and Baekkeskov, S. (2000) Am. J. Physiol. 279, E684-E694 |
| 20. | Gilon, P., Bertrand, G., Loubatieres-Mariani, M. M., Remacle, C., and Henquin, J. C. (1991) Endocrinology 129, 2521-2529 |
| 21. | Kim, J., Richter, W., Aanstoot, H. J., Shi, Y., Fu, Q., Rajotte, R., Warnock, G., and Baekkeskov, S. (1993) Diabetes 42, 1799-1808 |
| 22. | Janjic, D., Maechler, P., Sekine, N., Bartley, C., Annen, A. S., and Wollheim, C. B. (1999) Biochem. Pharmacol. 57, 639-648 |
| 23. | Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A., and Wollheim, C. B. (1992) Endocrinology 130, 167-178 |
| 24. | Pralong, W. F., Spat, A., and Wollheim, C. B. (1994) J. Biol. Chem. 269, 27310-27314 |
| 25. | Karlsen, A. E., Hagopian, W. A., Grubin, C. E., Dube, S., Disteche, C. M., Adler, D. A., Barmeier, H., Mathewes, S., Grant, F. J., Foster, D., and Lernmark, A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8337-8341 |
| 26. | Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene (Amst.) 108, 193-199 |
| 27. | Miyake, S., Makimura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1320-1324 |
| 28. | Vandewalle, C. L., Falorni, A., Lernmark, A., Goubert, P., Dorchy, H., Coucke, W., Semakula, C., Van der Auwera, B., Kaufman, L., Schuit, F. C., Pipeleers, D. G., and Gorus, F. K. (1997) Diabetes Care 20, 1547-1552 |
| 29. | Maechler, P., Jornot, L., and Wollheim, C. B. (1999) J. Biol. Chem. 274, 27905-27913 |
| 30. | Maechler, P., Wang, H., and Wollheim, C. B. (1998) FEBS Lett. 422, 328-332 |
| 31. | Ishihara, I., and Wollheim, C. B (2000) Eur. J. Cell Biol. 79, 187 (abstr.) |
| 32. | Namchuk, M., Lindsay, L., Turck, C. W., Kanaani, J., and Baekkeskov, S. (1997) J. Biol. Chem. 272, 1548-1557 |
| 33. | Reetz, A., Solimena, M., Matteoli, M., Folli, F., Takei, K., and De Camilli, P. (1991) EMBO J. 10, 1275-1284 |
| 34. | Michalik, M., Nelson, J., and Erecinska, M. (1993) Diabetes 42, 1506-1513 |
| 35. | Sorenson, R. L., Garry, D. G., and Brelje, T. C. (1991) Diabetes 40, 1365-1374 |
| 36. | Smismans, A., Schuit, F., and Pipeleers, D. (1997) Diabetologia 40, 1411-1415 |
| 37. | Kawai, K., and Unger, R. H. (1983) Endocrinology 113, 111-113 |
| 38. | Baekkeskov, S., Aanstoot, H. J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H., and De Camilli, P. (1990) Nature 347, 151-156 |
| 39. | Christgau, S., Schierbeck, H., Aanstoot, H. J., Aagaard, L., Begley, K., Kofod, H., Hejnaes, K., and Baekkeskov, S. (1991) J. Biol. Chem. 266, 21257-21264 |
| 40. | Yamada, H., Otsuka, M., Hayashi, M., Nakatsuka, S., Hamaguchi, K., Yamamoto, A., and Moriyama, Y. (2001) Diabetes 50, 1012-1020 |
| 41. | Rorsman, P., Berggren, P. O., Bokvist, K., Ericson, H., Mohler, H., Ostenson, C. G., and Smith, P. A. (1989) Nature 341, 233-236 |
This article has been cited by other articles:
![]() |
P. Newsholme, L. Brennan, and K. Bender Amino Acid Metabolism, {beta}-Cell Function, and Diabetes Diabetes, December 1, 2006; 55(Supplement_2): S39 - S47. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Jensen, J. W. Joseph, O. Ilkayeva, S. Burgess, D. Lu, S. M. Ronnebaum, M. Odegaard, T. C. Becker, A. D. Sherry, and C. B. Newgard Compensatory Responses to Pyruvate Carboxylase Suppression in Islet beta-Cells: PRESERVATION OF GLUCOSE-STIMULATED INSULIN SECRETION J. Biol. Chem., August 4, 2006; 281(31): 22342 - 22351. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, G. Kouri, and C. B. Wollheim ER stress and SREBP-1 activation are implicated in {beta}-cell glucolipotoxicity J. Cell Sci., September 1, 2005; 118(17): 3905 - 3915. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Meyre, P. Boutin, A. Tounian, M. Deweirder, M. Aout, B. Jouret, B. Heude, J. Weill, M. Tauber, P. Tounian, et al. Is Glutamate Decarboxylase 2 (GAD2) a Genetic Link between Low Birth Weight and Subsequent Development of Obesity in Children? J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2384 - 2390. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Herrero, B. Rubi, D. Sebastian, D. Serra, G. Asins, P. Maechler, M. Prentki, and F. G. Hegardt Alteration of the Malonyl-CoA/Carnitine Palmitoyltransferase I Interaction in the {beta}-Cell Impairs Glucose-Induced Insulin Secretion Diabetes, February 1, 2005; 54(2): 462 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Merglen, S. Theander, B. Rubi, G. Chaffard, C. B. Wollheim, and P. Maechler Glucose Sensitivity and Metabolism-Secretion Coupling Studied during Two-Year Continuous Culture in INS-1E Insulinoma Cells Endocrinology, February 1, 2004; 145(2): 667 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Anno, S. Uehara, H. Katagiri, Y. Ohta, K. Ueda, H. Mizuguchi, Y. Moriyama, Y. Oka, and Y. Tanizawa Overexpression of constitutively activated glutamate dehydrogenase induces insulin secretion through enhanced glutamate oxidation Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E280 - E285. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Le Gurun, D. Martin, A. Formenton, P. Maechler, D. Caille, G. Waeber, P. Meda, and J.-A. Haefliger Connexin-36 Contributes to Control Function of Insulin-producing Cells J. Biol. Chem., September 26, 2003; 278(39): 37690 - 37697. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Liu, H. Cheng, H. Drought, M. J. MacDonald, G. W. G. Sharp, and S. G. Straub Activation of the KATP channel-independent signaling pathway by the nonhydrolyzable analog of leucine, BCH Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E380 - E389. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Meijer Amino Acids as Regulators and Components of Nonproteinogenic Pathways J. Nutr., June 1, 2003; 133(6): 2057S - 2062. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, P. Maechler, P. A. Antinozzi, L. Herrero, K. A. Hagenfeldt-Johansson, A. Bjorklund, and C. B. Wollheim The Transcription Factor SREBP-1c Is Instrumental in the Development of beta -Cell Dysfunction J. Biol. Chem., May 2, 2003; 278(19): 16622 - 16629. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kelly, C. Li, Z. Gao, C. A. Stanley, and F. M. Matschinsky Glutaminolysis and Insulin Secretion: From Bedside to Bench and Back Diabetes, December 1, 2002; 51(90003): S421 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bertrand, N. Ishiyama, M. Nenquin, M. A. Ravier, and J.-C. Henquin The Elevation of Glutamate Content and the Amplification of Insulin Secretion in Glucose-stimulated Pancreatic Islets Are Not Causally Related J. Biol. Chem., August 30, 2002; 277(36): 32883 - 32891. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Brennan, A. Shine, C. Hewage, J. P. G. Malthouse, K. M. Brindle, N. McClenaghan, P. R. Flatt, and P. Newsholme A Nuclear Magnetic Resonance-Based Demonstration of Substantial Oxidative L-Alanine Metabolism and L-Alanine-Enhanced Glucose Metabolism in a Clonal Pancreatic {beta}-Cell Line : Metabolism of L-Alanine Is Important to the Regulation of Insulin Secretion Diabetes, June 1, 2002; 51(6): 1714 - 1721. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||